Search results
Results From The WOW.Com Content Network
ELIQUIS (apixaban) This product information is intended only for residents of the United States. for Healthcare professionals: Visit www.eliquis.com for U.S. Physician Prescribing Information
For more information about how insurance covers ELIQUIS and co-pay assistance for eligible, commercially-insured patients, visit ELIQUIS patient support or call 855-354-7847. Assistance for uninsured patients
Apixaban, sold under the brand name Eliquis, is an anticoagulant medication used to treat and prevent blood clots and to prevent stroke in people with nonvalvular atrial fibrillation through directly inhibiting factor Xa.
See Important Safety Info, including Boxed WARNINGS. Request ELIQUIS® samples and get resources for HCPs & Patients, including savings offers & starter guides.
The FDA granted approval of the generic apixaban applications to Micro Labs Limited and Mylan Pharmaceuticals Inc. Please contact the manufacturers for information about the medicine’s...
(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) approved ELIQUIS ® (apixaban) to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.
Given today’s decision, the earliest that generic manufacturers are permitted to launch their apixaban products is April 1, 2028, subject to additional appeals and challenges. We believe in the value of science behind Eliquis and its therapeutic potential for patients, and the underlying intellectual property protecting these innovations.
Eliquis is a brand name of apixaban, approved by the FDA in the following formulation(s): ELIQUIS (apixaban - tablet;oral) Manufacturer: BRISTOL MYERS SQUIBB Approval date: December 28, 2012 Strength(s): 2.5MG , 5MG ; Has a generic version of Eliquis been approved? A generic version of Eliquis has been approved by the FDA.
FDA approval history for Eliquis (apixaban) used to treat Prevention of Thromboembolism in Atrial Fibrillation, Deep Vein Thrombosis Prophylaxis after Knee Replacement Surgery, Deep Vein Thrombosis Prophylaxis after Hip Replacement Surgery. Supplied by Bristol-Myers Squibb Company and Pfizer Inc.
Eliquis (apixaban) is used to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. Includes Eliquis side effects, interactions and indications.